Hanmi licenses UCN2 obesity drug candidate HM17321 to Genentech in $2.3bn deal
Hanmi Pharm has granted Genentech global rights to develop and commercialise HM17321, an investigational UCN2 analogue designed to drive weight loss while preserving lean mass